MC Mining is having a busy month in the capital raising front.
1) MC Mining has raised R84m staged in two tranches and
2) the Industrial Development Coporation (IDC) has extended the date for repayment of a R160m loan payable by MC Mining.
[Thread]
MC Mining is a coal exploration mining company.
MC Mining’s key projects include the Uitkomst Collier (metallurgical and thermal coal), Makhado Project (hard coking coal), Vele Colliery
(semi-soft coking and thermal coal), and the Soutpansberg Projects (coking and thermal coal).
MC Mining entered into a
staged R86,036,691 Convertible Advance and Subscription Agreement with South African based mining group, Senosi Group Investment Holdings Proprietary Limited (Senosi) .
This agreement has two tranches.
Tranche 1:
the initial share subscription by Senosi is limited to 38,363,909
new ordinary shares in MC Company’s to be issued at R1.20 per share, to raise R46,036,691 in equity. This will result in SGIH owing 19.9% of the MC Company’s issued shares.
Senosi has also conditionally agreed to subscribe for a 2nd tranche of new ordinary shares (together with the First Tranche Shares, at the issue price, raising R40m (the Second Tranche Funding), which, will result in Senosi holding an aggregate 31.71% stake MC Mining.
Total R46m Senosi loan will convert to the First Tranche Shares once the funds have been advanced, provided that South African Reserve Bank approval has been obtained.
1st Tranche Funding is secured against shares in MCM’s subsidiaries,Limpopo Coal Company and Harissa
Investment
1st tranche funding (R46m) will be used to settle the balance owing to the vendors of the Lukin and Salaita properties.
MCM to make payment of R35m under a deferred payment arrangement for land acquired under a sale and purchase agreement.
R11m will be used for working capital.
The second tranche funding will be used to advance development of the Makhado hard coking coal project, thermal coal project and for working capital.
MC Mining’s flagship Makhado Project is situated in the Soutpansberg Coalfield in Limpopo province.
Makhado has all required licences and authorisations and construction of Phase 1 of the project is expected to commence in Q1 of 2022 dependent on funding.
The Makhado Project mining area covers four farms and will be developed in two phases.
MC Mining owns all of the surface
rights where the opencast mining pits and related infrastructure will be situated.
The Phase 1 includes the scalped and screened Makhado run-of-mine coal being processed at the existing, modified Vele Colliery plant, producing 0.54 million tonnes per annum (Mtpa) of hard coking coal and 0.57Mtpa of a thermal coal by-product.
The Makhado hard coking coal project currently has 29 employees and contractors with 650 to be employed when Makhado Phase 1 hard coking coal project is operational.
MC Mining has a 67% interest in MC Company.
MC Company sold 20% of the project to the Makhado Colliery Community Development Trust.
6% sold to a black industrialist facilitating.
IDC acquired a 6.7% shareholding in terms of its existing
loan facility.
MC Mining has secured offtake agreements for 85% of the Makhado Phase 1 hard coking coal and all of the thermal coal by-product.
The offtake agreement with ArcelorMittal will result in ArcelorMittal purchasing between
350 000t & 450 000t of Phase 1 hard coking coal annually.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Forbes and Magnum Opus Acquisition (a publicly-traded special purpose acquisition company) announced a $200 million strategic investment from Binance, one of the world’s largest cryptocurrency and blockchain infrastructure providers.
Short 🧵
Forbes has been seeking $400mn of additional capital through a private placement as part of its plans to list in New York via a merger with special purpose acquisition company Magnum Opus Acquisition Limited.
Binance’s strategic investment will be through Binance’s assumption of subscription agreements representing $200 million of commitments in the $400 million private investment in public equity.
Transnet has concluded its deal roadshow and bond auction by adding more debt on the balance sheet.
Transnet raised R2.02bn of senior unsecured notes ranging from a tenor of 1-12 years.
Auction was well received and achieved an order book of R2.57 billion (1.28x subscribed).
🧵
Transnet went on an investor deal roadshow hoping to raise funds from the domestic debt capital market to create a liquidity headroom of R5bn-R7bn over next 12-18 months.
Only R3,5bn of Transnet’s total debt is supported by government guarantees and dates back to the 1999 FY.
You have a liquidity issue that is weighing heavily on your balance sheet and you default solution is to add more expensive debt to the balance sheet as a way to resolve that issue.
Foreign Direct Investment flows to South Africa increased to $41 billion in 2021 from $3 billion in 2020 largely driven by the share swap between Naspers and ita majority-owned subsidiary Prosus.
Who is Prosus and why did Naspers embark on the share swap?
[Thread]
When Naspers coughs, the entire JSE catches a cold.
The JSE had record trading volumes on 17 Aug 2021 and of the R148bn traded, Naspers and Prosus accounted for R125bn in value.
Naspers’s size on the JSE was 25.9% the JSE Shareholder Weighted Index in 2019 and 23.3% in 2021.
In 2019, Naspers decided to unbundle all of its internet interests outside of South Africa including the famous Tencent stake into a new company which was called Prosus.
Prosus got a primary listing on Euronext Amsterdam and a secondary listing on the JSE.
GSK Consumer Healthcare has rejected a bid from Unilever to acquire its consumer health joint venture with Pfizer for a total acquisition value of £50bn comprising £41.7bn in cash and £8.3bn in Unilever shares.
Pfizer owns 32% of the joint venture while GSK owns remaining 68%.
GSK had received 3 unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business.
GSK rejected all 3 proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects.
What is a competitive offer for the GSK/Pfizer?
It would be based on a multiple to earnings before interest, tax, depreciation and amortisation (EBITDA) in the high teens, potential synergies of 14 to 15 per cent and a premium of at least 25%,